NEWS RELEASE

Novel Polymer-Free Drug Coated Stent Demonstrates Significant Benefit in Efficacy Over Conventional Drug-Eluting Stent With Durable Polymer

San Francisco, USA, 24 September 2009 – Biosensors International Group, Ltd ("Biosensors", "Company", BIG:SP) today announced the four-month results from the First-In-Man ("FIM") trial of BioFreedom™, a novel polymer-free drug-coated stent ("DCS") which showed a significant reduction in in-stent late lumen loss over Boston Scientific's Taxus Liberté stent. These results were presented by the Principal Investigator, Professor Eberhard Grube, Helios Heart Center, Siegburg, Germany, as part of the Featured Clinical Trial session at the 21st annual Transcatheter Cardiovascular Therapeutics ("TCT") scientific symposium, sponsored by the Cardiovascular Research Foundation.

BioFreedom is a new, "polymer-free" Biolimus A9™-coated stent currently under development at Biosensors. Two versions of the product were studied in this trial - BioFreedom Standard Dose ("SD" with a drug dosage of 15.6 µg/ per mm of stent length) and BioFreedom Low Dose ("LD" with a drug dosage of 7.8 µg/ per mm of stent length). Due to the absence of polymer coating, the Company believes that the new stent will promote more rapid vessel healing and reduce the need for longer term anti-platelet medications. The four-month results of the BioFreedom trial have provided proof of concept for this new DCS technology, demonstrating that polymer-free release of an immunosuppressive drug from the abluminal (outside) surface of a porous metal stent is feasible, safe, and can be highly effective in addressing patients with coronary artery disease ("CAD").

In the recently-completed first cohort of the BioFreedom FIM trial, results demonstrated a significant reduction of in-stent late loss at four months in the two BioFreedom groups (SD and LD) when compared to the TAXUS™ Liberté™ group. (BioFreedom SD = 0.08mm vs BioFreedom LD = 0.12 mm vs. TAXUS Liberté = 0.37mm, $p < 0.0001$ & $p = 0.002$ respectively). In-stent late loss is defined as the amount of tissue that builds up inside the stent months after stent implantation and has long been considered a primary measure of device effectiveness.

An intravascular ultrasound ("IVUS") analysis of the neointimal tissue volume obstruction, a secondary measure of device effectiveness, was also conducted at four months. This was observed to be 6.6% for the TAXUS Liberté and was significantly lower at 1.3% in the BioFreedom SD arm ($p = 0.0003$), while the BioFreedom LD group showed a non-significant reduction (5.5%) in in-stent neointimal tissue volume compared with the TAXUS Liberté.

More/…

"The results from BioFreedom FIM are very significant as they demonstrate for the first time that a polymer free drug-coated stent is not only as safe at four months as a conventional drug-eluting stent with a durable polymer coating, but is even more effective at that same time point", commented Professor Grube. "I am excited about the BioFreedom polymer-free concept as ultimately it may allow us to consider reducing dual anti-platelet therapy duration with patients. However, additional clinical data will be needed to support this approach."

Mr Mike Kleine, President & CEO of Biosensors added, "With the addition of BioFreedom to our pipeline, we continue to lead the industry in both drug-eluting stent and drug-coated stent innovation. We will continue to invest in new market segments, leveraging our strong technology platform, including our proprietary drug, Biolimus A9.

BioFreedom FIM is a prospective, multi-centre study. It includes 182 patients who were randomized into three groups. The primary endpoint is in-stent late lumen loss at 12 months, and the major secondary endpoint was in-stent late lumen loss at four months in the first cohort. This first cohort includes 75 patients randomized into three arms: 25 patients in the SD arm, 26 patients in the LD arm and the remaining 24 patients in the Taxus Liberté control arm.

-Ends-

For further information or to arrange interviews, please contact:

On site at TCT: Susanne Meis: s.meis@biosensors.com +49 171 8918919

Office-based support: Richard Kenyon: richard@rkpr.co.uk +44 7831 569940

About Biosensors International Group, Ltd

Biosensors develops, manufactures and markets innovative medical devices used in interventional cardiology and critical care procedures. Biosensors is well-positioned to emerge as a leader in drug-eluting stents and has developed a pipeline of next-generation products that are being positioned to gain market share from traditional therapies such as conventional drug-eluting stents, bare-metal stenting and open-heart surgery. It has three separate stent programs, Gazelle, a bare-metal stent, *BioMatrix*® ,a drug eluting stent with a bioresorbable polymer, and BioFreedom™, a completely polymer-free drug-eluting stent in development. For more information, please visit www.biosensors.com.